Edition:
United Kingdom

Fibrocell Science Inc (FCSC.OQ)

FCSC.OQ on NASDAQ Stock Exchange Capital Market

0.69USD
8 Dec 2017
Change (% chg)

$0.02 (+2.51%)
Prev Close
$0.68
Open
$0.70
Day's High
$0.70
Day's Low
$0.67
Volume
87,411
Avg. Vol
32,022
52-wk High
$4.59
52-wk Low
$0.67

Summary

Name Age Since Current Position

Douglas Swirsky

47 2016 Chairman of the Board

John Maslowski

42 2017 President, Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer

Lisa Embon

2017 Vice President - of Corporate Accounting , Controller

Kelvin Moore

66 2013 Lead Independent Director

Julian Kirk

42 2012 Director

Marcus Smith

60 2012 Director

Marc Mazur

56 2010 Independent Director

Christine St.Clare

66 2013 Independent Director

Biographies

Name Description

Douglas Swirsky

Mr. Douglas J. Swirsky is Chairman of the Board of Fibrocell Science, Inc. Mr. Swirsky has served as Senior Vice President, Chief Financial Officer, Treasurer and Corporate Secretary of GenVec, Inc. Mr. Swirsky previously held investment banking positions at UBS, PaineWebber, Morgan Stanley, and Legg Mason. Prior to joining GenVec, Mr. Swirsky was with Stifel Nicolaus where he served as a Managing Director and the Head of Life Sciences Investment Banking. He received his B.S. in Business Administration from Boston University and his M.B.A. from the Kellogg School of Management at Northwestern University. Mr. Swirsky served as a member of the Board of Directors of PolyMedix, Inc. until March 2013.

John Maslowski

Mr. John Maslowski is President, Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer of the Company. Mr. Maslowski joined Fibrocell in 2005 and most recently served as the Company's Senior Vice President of Scientific Affairs with oversight of research and development, clinical and regulatory affairs. Previously, he was Vice President of Operations with responsibility for manufacturing and quality operations. Prior to joining Fibrocell, he held various positions at Wyeth Pharmaceuticals, Inc., Merck & Co., Inc. and Teva Pharmaceutical Industries Ltd. Mr. Maslowski earned a B.S. in Biology from Ursinus College and an M.S. in Biology from Villanova University.

Lisa Embon

Ms. Lisa A. Embon Vice President - of Corporate Accounting , Controller of the Company. Ms. Embon has served as a consultant to the Company through AC Lordi since September 2009. Ms. Embon joined AC Lordi in 2003 and became a Principal, Accounting Services of AC Lordi in 2015. Prior to her work with the Company, Ms. Embon provided audit and business advisory services to companies ranging from private start-ups to multinational corporations in the life sciences, manufacturing and healthcare industries. Ms. Embon held key accounting positions for AC Lordi clients, including SEC Reporting Manager, Director of Accounting & Finance, and Controller. Prior to joining AC Lordi, Ms. Embon worked at PricewaterhouseCoopers, LLC from 1986 to 1993. Ms. Embon earned a B.A. in Business Administration from Ms. Embon has served as a consultant to the Company through AC Lordi since September 2009. Ms. Embon joined AC Lordi in 2003 and became a Principal, Accounting Services of AC Lordi in 2015. Prior to her work with the Company, Ms. Embon provided audit and business advisory services to companies ranging from private start-ups to multinational corporations in the life sciences, manufacturing and healthcare industries. Ms. Embon held key accounting positions for AC Lordi clients, including SEC Reporting Manager, Director of Accounting & Finance, and Controller. Prior to joining AC Lordi, Ms. Embon worked at PricewaterhouseCoopers, LLC from 1986 to 1993. Ms. Embon earned a B.A. in Business Administration from Gettysburg College.

Kelvin Moore

Mr. Kelvin Moore is the Lead Independent Director of Fibrocell Science Inc. He has 30 years of experience in a wide range of roles within the banking industry. From March 2009 to late 2010, Mr. Moore served as the consultant sales director for the UK based Seaborne Group developing their business in building constructions from converting shipping sea containers. From July 2008 to September 2010, Mr. Moore was a director of Acorn Cultural Developments Limited which is developing a social networking site. Between June 2004 and May 2008, Mr. Moore was a senior advisor with Exit Strategy Planning dealing with the sale of businesses. Currently, he runs his own consulting business providing mentoring to owners of SMEs. Mr. Moore holds a London University Degree in Geography and Pure Mathematics.

Julian Kirk

Mr. Julian P. Kirk is the Director of Fibrocell Science Inc. Since its inception, Mr. Kirk has worked with several portfolio companies of Third Security, LLC’s managed investment funds and is involved with oversight of Third Security, LLC’s internal operations. Since August 2010, he has served on the board of the New River Valley Economic Development Alliance. From October 2006 until December 2011, he served as member of the Board of Directors of IntelliMat, Inc. and as Co-Chairman of the Board between September 2008 and December 2011. From September 2005 until December 2011, Mr. Kirk served as President of Harvest Pharmaceuticals Inc. Mr. Kirk also served as Chairman of the Board of Managers of ECDS, LLC from June 2008 until March 2010. Mr. Kirk graduated as an Echols Scholar from the University of Virginia.

Marcus Smith

Mr. Marcus E. Smith is the Director of Fibrocell Science Inc. Mr. Smith joined Third Security, LLC upon its inception and has since been principally responsible for legal matters and transaction execution. From August 1996 to April 2004, Mr. Smith served as Senior Vice President, General Counsel, Secretary and member of the Board of Directors of New River Pharmaceuticals Inc. Mr. Smith received his B.B.A. and his J.D. from the University of Georgia.

Marc Mazur

Mr. Marc B. Mazur is the Independent Director of Fibrocell Science Inc. Mr. Mazur has served as a director of Fibrocell since April 2010. Since May 2009, Mr. Mazur has served as the Chairman of Elsworthy Capital Management Ltd., a London-based European equity hedge fund. From October 2006 until December 2009, Mr. Mazur served as the CEO of Brevan Howard U.S. Asset Management, the U.S. arm of London-based Brevan Howard. In 2001, Mr. Mazur founded Ambassador Capital Group, a privately held investment and advisory entity providing capital, business development and strategic planning advice to companies in the healthcare, financial services and real estate fields. Mr. Mazur received his B.A. in political science from Columbia University in 1981 and a J.D. from Villanova University in 1984.

Christine St.Clare

Ms. Christine Thompson St.Clare is the Independent Director of Fibrocell Science, Inc. Ms. St.Clare recently completed a 35-year career with KPMG where she served a four-year term on the firm’s Board of Directors and chaired the board’s Audit and Finance Committee. As an Audit Partner, she served as the Engagement Partner for some of KPMG’s clients. She then assumed the position as an Advisory Partner for the firm’s Advisory Practice focusing on the Internal Audit, Risk and Compliance Practice. Concurrently, she was the Partner-in-Charge of the Southeast Consumer Markets practice. She currently serves on the board of directors of Polymer Group, Inc. and serves as the Chair of the audit committee. She also serves on advisory boards of Houlihan Lokey, a midsize global, advisory-focused investment bank, Women Corporate Directors, and Emory University’s Goizueta Business School.

Basic Compensation